What should a laboratory verify when selecting an AOD-9604 supplier in Australia?
When a laboratory evaluates an AOD-9604 supplier in Australia, the first filter is documentary completeness rather than list price. A research-grade peptide consignment should arrive with a lot number identical on the vial label, the packing list and the COA. The COA should name the substance unambiguously (AOD-9604 / AOD9604), state a molecular formula or monoisotopic mass consistent with the intended sequence, and identify the methods used for identity and purity. A tyrosine-extended 177–191 fragment is not interchangeable with unmodified 177–191 or with intact growth hormone, and the paperwork should not blur those identities.
Specification fields that belong in a procurement file include reversed-phase HPLC purity, electrospray mass confirmation, appearance of the lyophilised solid, and, where offered, net peptide content, counter-ion identity and water content. Each field should carry a method reference and a numerical result. Acceptance criteria are laboratory-defined: a stated HPLC purity threshold, a mass within a defined error of theory, and no unspecified major peaks above an agreed reporting threshold. Write those criteria into the purchase specification before ordering so that non-conforming lots can be quarantined on receipt.
Ask whether stock is held in Australia, whether dispatch is tracked, and whether historical COAs for the same catalogue item are available for trend review. A supplier that cannot produce a batch-specific chromatogram and a mass spectrum is not equivalent to one that can. Cross-check that the COA laboratory name, instrument type and date of analysis are present. Retain the commercial invoice, consignment identifier and COA together so that an audit trail exists from receiving log to storage location. None of this documentation authorises human use; it only supports research identity and quality decisions.
How is AOD-9604 identity confirmed before a research lot is accepted?
Identity for a synthetic peptide is a mass-and-sequence problem. Calculate the theoretical monoisotopic mass of AOD-9604 from the intended amino-acid sequence, including the N-terminal tyrosine if that analogue is specified. A COA that reports only a “matches standard” tick without an m/z value is incomplete. Typical ESI-MS documentation lists observed [M+2H]2+ or [M+3H]3+ ions, the deconvoluted neutral mass, and the delta versus theory. Confirm that the charge-state series is plausible and that sodium or potassium adducts are annotated.
Orthogonal identity is stronger than a single mass. Tandem mass spectrometry can support the sequence through b- and y-ion series, particularly around the tyrosine extension. Retention time is supporting evidence only with a qualified reference standard and a locked method; it does not prove sequence.
Published detection work shows that AOD9604 is amenable to mass-spectrometric methods and that in vitro metabolism can generate related species that must be distinguished from the parent peptide in matrix studies (PMID:25208511). Define the parent mass and the principal HPLC peak so degradants are not integrated into “purity”. Work on the WADA hGH isoform immunoassay reported that AOD-9604 did not influence that format, which supports treating this fragment as analytically distinct from intact human growth hormone (DOI:10.1002/dta.1557). Identify the peptide by chemistry, not by hormone-assay cross-reactivity. On receipt, compare the COA mass with an independent calculation; a mismatch beyond method accuracy is an identity failure. If the laboratory has LC–MS access, a confirmatory run on the received lot is the most direct check against substitution or mislabelling. Record the theoretical mass, observed mass and delta in the receiving notebook so later users of the lot do not rely on memory.
Which HPLC purity and related-substance results belong on an AOD-9604 COA?
Reversed-phase HPLC remains the workhorse purity method for research peptides. A usable AOD-9604 chromatogram identifies column chemistry (typically C18), particle size, mobile-phase pair (water/acetonitrile with trifluoroacetic or formic acid), gradient, detection wavelength and integration parameters. Purity is the area percent of the principal peak versus summed peaks above a stated reporting threshold. Without that threshold, area percent is not comparable between lots. Diode-array peak-purity indices can flag co-elution but do not replace mass confirmation of the main peak.
Related-substance reporting should list the number of unspecified impurities above the reporting threshold and the area of the largest single unspecified impurity. Deletion sequences, truncation products and residual protecting-group species are typical process-related peaks. Oxidation or deamidation products, where the sequence is susceptible, should be integrated separately. System suitability—blank, replicate introductions, tailing factor and resolution to the nearest impurity—belongs in the method file.
Do not treat “>98% HPLC” as a complete specification. Ask whether purity is area percent or a mass-balance value corrected for water and counter-ion. Trifluoroacetate or acetate can be a substantial mass fraction of a lyophilised peptide; net peptide content is the figure to use when preparing gravimetric standards. Overlay chromatograms from successive lots only when the method is unchanged. A new impurity in a previously empty window is a process-change signal. If the main peak fronts or shoulders, request an expanded chromatogram before releasing the material into a quantitative assay. HPLC purity characterises that lot’s chromatographic profile; it does not replace identity by mass. Archive the PDF chromatogram with the lot so investigations retrieve the original integration.
What do published detection studies mean for AOD-9604 specifications?
Two peer-reviewed analytical papers are useful when writing an AOD-9604 identity specification. Cox and co-workers described detection and in vitro metabolism of AOD9604, placing the peptide in a mass-spectrometric detection context and treating metabolic transformation as an experimental theme for this analyte (PMID:25208511). For purchasing laboratories, “AOD-9604” on a vial is a parent-compound claim. If a protocol incubates the peptide in biological matrices, it must define how parent will be distinguished from transformation products, and the starting HPLC–MS profile should be recorded first. A single purity percentage without a chromatogram or mass cannot support that distinction.
A separate study examined whether AOD-9604 influences the WADA human growth hormone isoform immunoassay and reported that it does not (DOI:10.1002/dta.1557). That is an immunoassay-specificity result. It cautions against using growth-hormone immunoassays as a substitute identity test and against implying analytical equivalence to intact hGH. Identity should rest on sequence, mass and chromatography. Kit-specific verification remains necessary if immunoassay method work is in scope.
Neither paper is a COA or a pharmacopoeial monograph. They do not set HPLC area-percent limits or net-content specifications for commercial research lots. Those limits remain the buyer’s acceptance criteria. The literature does enforce nomenclature discipline: AOD-9604 as a discrete analyte, transformable in vitro, and distinguishable from hGH in at least one isoform immunoassay. Catalogue text should use that discrete identity. File journal articles as method context and the lot COA as the primary quality record; a 2013 or 2015 paper does not characterise the vial on the bench.
How should lot traceability and Australian dispatch records be organised?
Lot traceability converts a supplier relationship into a reconstructable chain of custody. At goods-in, record the catalogue code, declared quantity, lot number, COA number and consignment tracking identifier in one receiving log. The COA lot number must match the vial; a generic product COA covering multiple lots is not traceability. Vials that share a lot share one analytical package, but each vial still needs a unique storage location.
Australian procurement files benefit from local stock and tracked dispatch because they shorten the documentary gap between order and receipt. A domestic consignment identifier, a dispatch timestamp and a delivery scan belong with the COA. Laboratories sourcing Australian stock avoid mixing international shipping files with analytical files. Tracked dispatch answers which parcel arrived; HPLC–MS answers what chemical was in the vial.
Batch packs commonly include the HPLC chromatogram, mass spectrum, purity statement and sometimes water or residual-solvent results. For multi-vial orders, a single lot is preferable, because mixed lots prevent one set of acceptance criteria from applying to the whole order. Trend files of purity and mass across successive lots help detect drift in related-substance profiles. Keep material quarantined until identity and purity checks against the purchase specification are complete. Record failures as non-conformances. Labelling must state research use only. Traceability protects experimental data integrity; it does not authorise unapproved human applications. Search disambiguation belongs in the same file plan: AOD also means aerosol optical depth in Australian atmospheric evaluations and alcohol and other drugs in health-workforce papers, so use the full token AOD-9604 in purchase orders and filenames (DOI:10.1016/j.atmosenv.2022.119054; DOI:10.1016/j.colegn.2021.03.006).
Order Aod 9604 with documentation
If this guide helped you evaluate Aod 9604 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Aod 9604 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Can a journal article replace the COA when procuring AOD-9604 for research?
No. Detection and immunoassay papers describe the analyte class and method context; they do not characterise a commercial lot. Release decisions require a batch-specific COA with HPLC purity, mass confirmation, matching lot codes and a dated method summary. Archive literature separately from goods-in records.
What documents should an AOD-9604 supplier in Australia provide with each lot?
At minimum, a COA naming AOD-9604, the lot number, an HPLC chromatogram with an integration threshold, a mass-spectrometric identity result, and the analysis date. Pair these with a tracked-dispatch identifier and an invoice that repeats the lot code. Optional fields include net peptide content, counter-ion and water. Material is for laboratory research only.
Why is immunoassay non-interference relevant to AOD-9604 identity files?
Published work reported that AOD-9604 did not influence the WADA hGH isoform immunoassay, which supports treating the fragment as chemically distinct from intact growth hormone. Laboratories should still confirm identity by mass and sequence-related data, and should not use hormone kits as a substitute COA.
Why do “AOD Australia” searches return papers that are not about this peptide?
In Australian literature, AOD commonly means aerosol optical depth or alcohol and other drugs. Those usages dominate some result lists. Procurement files should use the full token AOD-9604 or AOD9604 so atmospheric and health-services PDFs are not mixed with peptide COAs.
How should mixed lots be handled on a multi-vial research order?
Each lot needs its own COA, chromatogram and mass result, and its own quarantine decision. A single-lot order is simpler because one acceptance specification applies to every vial. Do not average purity values across lots or apply one certificate to unmatched labels.
References
- PMID:25208511 — Detection and in vitro metabolism of AOD9604 — Drug Test Anal — 2015
- DOI:10.1002/dta.1557 — AOD‐9604 does not influence the WADA hGH isoform immunoassay — Drug Testing and Analysis — 2013
- DOI:10.1016/j.atmosenv.2022.119054 — Evaluation and comparison of MERRA-2 AOD and DAOD with MODIS DeepBlue and AERONET data in Australia — Atmospheric Environment — 2022
- DOI:10.1016/j.colegn.2021.03.006 — The demographic profile of alcohol and other drug (AOD) nurses in Australia: Experienced, highly qualified… and endangered? — Collegian — 2022
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
